HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is a frequently diagnosed cancer and a leading cause of cancer-related death worldwide. Its rapid progression, combined with the limited treatment options at late stages, imposes the need for early detection and aggressive intervention. Based on the knowledge that hepatocarcinogenesis is significantly influenced by histone acetylation, we directed our search for novel HCC therapeutics among histone deacetylation inhibitors (HDACi). The aim of the present study was to investigate the effect of HDAC1/2 inhibitor Romidepsin in the well-established mouse model of diethylnitrosamine (DEN)-induced HCC.

Materials and methods

C56BL/6 mice were treated with Romidepsin at the critical point of 10 months after DEN challenge and their livers wer

SUBMITTER: Afaloniati H 

PROVIDER: S-EPMC7304783 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature